Lab21 appoints new CEO
Lab21 has announced the appointment of Graham Mullis as its new CEO. Graham has held executive positions at FTSE and Nasdaq listed medical device companies including 1-800 Contacts Inc and Biocompatibles International PLC and pharmaceutical roles at Hoechst Roussel Ltd and R P Scherer Ltd. He has experience in successfully launching new businesses and technologies in healthcare markets, with IPO and extensive M&A experience at a variety of medical and pharmaceutical companies. Graham has an MBA from Warwick Business School and BSc in biochemistry with Physiology from Southampton University.
Graham joins Lab21 from Optivue Ltd, a company formed to develop and license pharmaceutical & medical device applications in optical products, where he is a co-founder.
Most read news
Other news from the department people

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.